Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Departamentos, Grupos de Investigación e Institutos >
Departamento de Microbiología >
DM - Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/28452

Title: Pharmacogenetics of osteoporosis: Towards novel theranostics for personalized medicine?
Authors: Rojo-Venegas, Karen
Aguilera Gómez, Margarita
Cañadas-Garre, María Luisa
García Sánchez, Antonio
Contreras-Ortega, Carlos
Calleja Hernández, Miguel Ángel
Issue Date: 18-Oct-2013
Abstract: Osteoporosis is a complex multifactorial bone disorder with a strong genetic basis. It is the most common, severe, progressive skeletal illness that has been increasing, particularly in developed countries. Osteoporosis will no doubt constitute a serious clinical burden in healthcare management in the coming decades. The genetics of osteoporosis should be analyzed from both the disease susceptibility and the pharmacogenetic treatment perspectives. The former has been widely studied and discussed, while the latter still requires much more information and research. This article provides a synthesis of the literature on the genetics of osteoporosis and an update on progress made in pharmacogenetics of osteoporosis in recent years, specifically regarding the new molecular targets for antiresorptive drugs. In-depth translation of osteoporosis pharmacogenetics approaches to clinical practice demands a new vision grounded on the concept of "theranostics," that is, the integration of diagnostics for both disease susceptibility testing, as well as for prediction of health intervention outcomes. In essence, theranostics signals a broadening in the scope of inquiry in diagnostics medicine. The upcoming wave of theranostics medicine also suggests more distributed forms of science and knowledge production, both by experts and end-users of scientific products. Both the diagnosis and personalized treatment of osteoporosis could conceivably benefit from the emerging postgenomics field of theranostics.
Keywords: Theranostics
Pharmacogenetics
Osteoporosis
Novel diagnostics
Atniresorptive drugs
Clinical translation
BMD
Fractures
URI: http://hdl.handle.net/10481/28452
ISSN: 1536-2310
1557-8100
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Appears in Collections:DM - Artículos

Files in This Item:

File Description SizeFormat
2012_Karen_OMICS.pdf633.42 kBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada